Bosutinib (BOS) Vs Imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE Trial Meeting Abstract
| Authors: | Gambacorti-Passerini, C.; Deininger, M.; Mauro, M. J.; Chuah, C.; Kim, D. W.; Reilly, L.; Jeynes-Ellis, A.; Leip, E.; Bardy-Bouxin, N.; Hochhaus, A.; Brummendorf, T. H.; Cortes, J. E.; on behalf of the BFORE Study Investigators |
| Abstract Title: | Bosutinib (BOS) Vs Imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE Trial |
| Meeting Title: | 46th Congress of the Italian Society of Hematology |
| Journal Title: | Haematologica |
| Volume: | 102 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2017 Oct 15-18 |
| Meeting Location: | Rome, Italy |
| ISSN: | 0390-6078 |
| Publisher: | Ferrata Storti Foundation |
| Date Published: | 2017-10-13 |
| Start Page: | 20 |
| Language: | English |
| ACCESSION: | WOS:000440251200045 |
| PROVIDER: | wos |
| PMCID: | PMC5642103 |
| Notes: | Meeting Abstract: C031 -- Source: Wos |
MSK Authors
-
267Mauro